Medivir (MVRBF) To Merge Research And Development And Implement Changes Within The Management Group

STOCKHOLM, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) (STO:MVIRB) today announces that, as the next step in the company's optimisation process, its research and development operations will be merged into a joint unit as of 1 October 2015, headed by Richard Bethell who will hold the new title of EVP Research & Development. The new unit will span the entire process, from the early research to the late-stage development phases.